messag report result larg within investor
expect compani cite modest impact oper due
continu abil execut clinic trial includ intiat rolonti same-
day dose studi complet enrol cohort upcom
mileston includ cohort readout mid- respect
pdufa date rolonti updat estim account result
modest impact continu execut clinic trial
immun effect management highlight find innov way continu
busi oper note complet enrol cohort well
initi anoth clinic trial rolonti said note uncertainti around
potenti data readout cohort enrol egfr patient
random across multipl dose level schedul
initi rolonti day dose studi recal rolonti
long-act granulocyt coloni stimul factor g-csf upcom
pdufa date chemotherapy-induc neutropenia long-act g-csf agent
repres potenti competit includ neulasta biosimilar fulphila
udenyca highlight requir patient return
clinic day chemotherapi administr receiv g-csf
potenti abil rolonti undergo same-day dose could improv patient conveni
reduc clinic visit
poziotinib cohort on-track read
respect recal cohort independently-pow potenti
registration-en singl arm cohort evalu poziotinib
egfr non-smal cell lung cancer nsclc patient respect low
convict success given disappoint result cohort egfr
start dose mg qd potenti competit headwind
poziotinib eventu commerci link
updat estim account result maintain neutral end
quarter cash invest modestli decreas oper
expens forecast account result
page analyst certif import disclosur
valuat risk
valu use discount cash flow analysi use wacc consist clinical-
stage biotech compani cover proof-of-concept data well termin growth rate risk includ regulatori
commerci setback potenti emerg new competitor lower product sale expect dilut financ beyond
assum
page analyst certif import disclosur
servic revenu
amort intang asset
total cost expens
interest incom net
interest expens
loss extinguish debt
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
